Different kinds of stem cells in the development of SARS-CoV-2 treatments

doi:10.4252/wjsc.v13.i5.439

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6570)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

370

WORD

182

HTML

3149

Figures (1-2)

284

Tables (1-3)

272

Sum=4257

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

324

Download

646

Sum=970

Publishing Process of This Article

Item

Count

Browse

388

Download

955

Sum=1343

May 26, 2021 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. May 26, 2021; 13(5): 439-451
Published online May 26, 2021. doi: 10.4252/wjsc.v13.i5.439

Table 3 Advantages and disadvantages of stem cells in clinical trials

	Advantages	Disadvantages
ESCs
	High differentiation capability which can recapitulate appropriate cell-intrinsic phenotypes	Ethical dilemma
	Grow up in the laboratory from a single cell for later transplantation	Tumorigenesis risk
MSCs
	Immunomodulatory properties	A narrower spectrum of differentiation
	Widespread availability and accessibility	High expression of ACE2 receptor
	Limited ethical concerns	Expression of MHC I and II

ESCs: Embryonic stem cells; MSCs: Mesenchymal stem cells; ACE2: Angiotensin-converting enzyme 2; MHC: Major histocompatibility complex.

Citation: Mata-Miranda MM, Sanchez-Brito M, Vazquez-Zapien GJ. Different kinds of stem cells in the development of SARS-CoV-2 treatments. World J Stem Cells 2021; 13(5): 439-451
URL: https://www.wjgnet.com/1948-0210/full/v13/i5/439.htm
DOI: https://dx.doi.org/10.4252/wjsc.v13.i5.439